Literature DB >> 29436492

Allosterism within δ Opioid-κ Opioid Receptor Heteromers in Peripheral Sensory Neurons: Regulation of κ Opioid Agonist Efficacy.

Blaine A Jacobs1, Miryam M Pando1, Elaine Jennings1, Teresa A Chavera1, William P Clarke1, Kelly A Berg2.   

Abstract

There is abundant evidence for formation of G protein-coupled receptor heteromers in heterologous expression systems, but little is known of the function of heteromers in native systems. Heteromers of δ and κ opioid receptors (DOR-KOR heteromers) have been identified in native systems. We previously reported that activation of DOR-KOR heteromers expressed by rat pain-sensing neurons (nociceptors) produces robust, peripherally mediated antinociception. Moreover, DOR agonist potency and efficacy is regulated by KOR antagonists via allosteric interactions within the DOR-KOR heteromer in a ligand-dependent manner. Here we assessed the reciprocal regulation of KOR agonist function by DOR antagonists in adult rat nociceptors in culture and in a behavioral assay of nociception. Naltrindole enhanced the potency of the KOR agonist 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenyl-2-pyrrolidin-1-ylethyl]acetamide (ICI-199441) 10- to 20-fold, but did not alter responses to 2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide (U50488). By contrast, the potency of U50488 was enhanced 20-fold by 7-benzylidenenaltrexone. The efficacy of 6'-guanidinonaltrindole (6'-GNTI) to inhibit nociceptors was blocked by small interfering RNA knockdown of DOR or KOR. Replacing 6'-GNTI occupancy of DOR with either naltrindole or 7-benzylidenenaltrexone abolished 6'-GNTI efficacy. Further, peptides derived from DOR transmembrane segment 1 fused to the cell membrane-penetrating HIV transactivator of transcription peptide also blocked 6'-GNTI-mediated responses ex vivo and in vivo, suggesting that 6'-GNTI efficacy in nociceptors is due to its positive allosteric regulation of KOR via occupancy of DOR in a DOR-KOR heteromer. Together, these results provide evidence for the existence of functional DOR-KOR heteromers in rat peripheral sensory neurons and that reciprocal, ligand-dependent allosteric interactions occur between the DOR and KOR protomers.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29436492      PMCID: PMC5832326          DOI: 10.1124/mol.117.109975

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

Review 1.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.

Authors:  Maria Waldhoer; Jamie Fong; Robert M Jones; Mary M Lunzer; Shiv K Sharma; Evi Kostenis; Philip S Portoghese; Jennifer L Whistler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

3.  Coexpression of delta-opioid receptors with micro receptors in GH3 cells changes the functional response to micro agonists from inhibitory to excitatory.

Authors:  Andrew C Charles; Natalya Mostovskaya; Kathleen Asas; Christopher J Evans; Megan L Dankovich; Tim G Hales
Journal:  Mol Pharmacol       Date:  2003-01       Impact factor: 4.436

Review 4.  G protein-coupled receptors: walking hand-in-hand, talking hand-in-hand?

Authors:  Henry F Vischer; Anne O Watts; Saskia Nijmeijer; Rob Leurs
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

5.  Dual regulation of δ-opioid receptor function by arachidonic acid metabolites in rat peripheral sensory neurons.

Authors:  Laura C Sullivan; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2015-01-30       Impact factor: 4.030

6.  Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer.

Authors:  Xavier Guitart; Gemma Navarro; Estefania Moreno; Hideaki Yano; Ning-Sheng Cai; Marta Sánchez-Soto; Sandeep Kumar-Barodia; Yamini T Naidu; Josefa Mallol; Antoni Cortés; Carme Lluís; Enric I Canela; Vicent Casadó; Peter J McCormick; Sergi Ferré
Journal:  Mol Pharmacol       Date:  2014-08-05       Impact factor: 4.436

7.  The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition.

Authors:  K Siddiquee; J Hampton; D McAnally; Lt May; Lh Smith
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

8.  Rapid modulation of micro-opioid receptor signaling in primary sensory neurons.

Authors:  Kelly A Berg; Amol M Patwardhan; Teresa A Sanchez; Yamille M Silva; Kenneth M Hargreaves; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2007-03-08       Impact factor: 4.030

9.  Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons.

Authors:  Raphael Rozenfeld; Ittai Bushlin; Ivone Gomes; Nikos Tzavaras; Achla Gupta; Susana Neves; Lorenzo Battini; G Luca Gusella; Alexander Lachmann; Avi Ma'ayan; Robert D Blitzer; Lakshmi A Devi
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

10.  Allosteric modulation in monomers and oligomers of a G protein-coupled receptor.

Authors:  Rabindra V Shivnaraine; Brendan Kelly; Krishana S Sankar; Dar'ya S Redka; Yi Rang Han; Fei Huang; Gwendolynne Elmslie; Daniel Pinto; Yuchong Li; Jonathan V Rocheleau; Claudiu C Gradinaru; John Ellis; James W Wells
Journal:  Elife       Date:  2016-05-06       Impact factor: 8.140

View more
  4 in total

1.  Signaling characteristics and functional regulation of delta opioid-kappa opioid receptor (DOP-KOP) heteromers in peripheral sensory neurons.

Authors:  Blaine A Jacobs; Miryam M Pando; Elaine M Jennings; Raehannah J Jamshidi; Joshua C Zamora; Teresa S Chavera; William P Clarke; Kelly A Berg
Journal:  Neuropharmacology       Date:  2019-02-15       Impact factor: 5.250

Review 2.  Strategies towards safer opioid analgesics-A review of old and upcoming targets.

Authors:  Balazs R Varga; John M Streicher; Susruta Majumdar
Journal:  Br J Pharmacol       Date:  2021-11-26       Impact factor: 9.473

Review 3.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

4.  Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox.

Authors:  Joshua C Zamora; Hudson R Smith; Elaine M Jennings; Teresa S Chavera; Varun Kotipalli; Aleasha Jay; Stephen M Husbands; Alex Disney; Kelly A Berg; William P Clarke
Journal:  Pharmacol Res Perspect       Date:  2021-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.